Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non-Small Cell Lung Cancer: A Case Report

Authors

Daniel A Fox
Christine Tran
Vincent Blot
David S Hong

Publication Date

5-1-2025

Journal

Journal of Immunotherapy and Precision Oncology

DOI

10.36401/JIPO-24-29

PMID

40066205

PMCID

PMC11891986

PubMedCentral® Posted Date

2-14-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Antibody-drug conjugates (ADCs) are a potent class of antineoplastic drugs that deliver cytotoxic agents via targeting with monoclonal antibodies; however, ADCs are associated with high rates of lung toxicities, limiting the therapeutic potential in many patients. We report a case of a patient with metastatic non-small cell lung cancer taking the ADC telisotuzumab vedotin (Teliso V) plus osimtertinib who developed ADC-induced pneumonitis despite clinical benefit. This patient was able to tolerate treatment for a prolonged period on a novel steroid regimen, using steroids when pneumonitis was asymptomatic but radiologically evident and as a daily suppressant. This treatment strategy may have implications in the broader management of ADC-interstitial lung disease/pneumonitis and underscores its potential mechanisms.

Published Open-Access

yes

Recommended Citation

Fox, Daniel A; Tran, Christine; Blot, Vincent; et al., "Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non-Small Cell Lung Cancer: A Case Report" (2025). Faculty, Staff and Student Publications. 3301.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/3301